Tomofumi Nakamura1, Benjamin Schaeffer2, Shinichi Tanigawa2, Rahul G Muthalaly2, Roy M John3, Gregory F Michaud3, Usha B Tedrow2, William G Stevenson4. 1. Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 2. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: william.g.stevenson@vanderbilt.edu.
Abstract
BACKGROUND: Catheter ablation for polymorphic ventricular tachycardia and ventricular fibrillation (PMVT/VF) may target triggering premature ventricular contractions (PVCs). Targeting ventricular scar has also been suggested, but data are limited. OBJECTIVE: The purpose of this study was to characterize the electrophysiological findings and ablation outcomes for patients with PMVT/VF and structural heart disease (SHD) compared to those with idiopathic VF. METHODS: Data from 32 consecutive patients (13 idiopathic VF, 19 SHD) with recurrent PMVT/VF who underwent catheter ablation were reviewed. RESULTS: A low-voltage area of myocardial scar was present in 15 of 19 patients with SHD. Sustained monomorphic ventricular tachycardia (SMVT) associated with scar was inducible and targeted in 8, 3 of whom had previous SMVT episodes separate from PMVT/VF episodes and 5 had no history of SMVT. Triggering PVCs were identified in 11 patients and arose from an area of endocardial scar in 6. Only scar ablation was performed in 8 patients who did not have triggering PVCs. All idiopathic VF patients underwent PVC ablation only. During a median of 540 days, 74% of SHD patients and 77% of idiopathic VF patients were free of recurrence, including 75% of those with only PVC ablation, 86% of those with scar plus PVC ablation, and 63% of those with only scar ablation. CONCLUSION: Patients with recurrent PMVT/VF and SHD often have a low-voltage scar associated with PVCs or inducible SMVT, which may also be the substrate for PMVT/VF. When present, substrate ablation targeting scar is a reasonable option for treatment of PMVT/VF even if PVCs are absent.
BACKGROUND: Catheter ablation for polymorphic ventricular tachycardia and ventricular fibrillation (PMVT/VF) may target triggering premature ventricular contractions (PVCs). Targeting ventricular scar has also been suggested, but data are limited. OBJECTIVE: The purpose of this study was to characterize the electrophysiological findings and ablation outcomes for patients with PMVT/VF and structural heart disease (SHD) compared to those with idiopathic VF. METHODS: Data from 32 consecutive patients (13 idiopathic VF, 19 SHD) with recurrent PMVT/VF who underwent catheter ablation were reviewed. RESULTS: A low-voltage area of myocardial scar was present in 15 of 19 patients with SHD. Sustained monomorphic ventricular tachycardia (SMVT) associated with scar was inducible and targeted in 8, 3 of whom had previous SMVT episodes separate from PMVT/VF episodes and 5 had no history of SMVT. Triggering PVCs were identified in 11 patients and arose from an area of endocardial scar in 6. Only scar ablation was performed in 8 patients who did not have triggering PVCs. All idiopathic VFpatients underwent PVC ablation only. During a median of 540 days, 74% of SHD patients and 77% of idiopathic VFpatients were free of recurrence, including 75% of those with only PVC ablation, 86% of those with scar plus PVC ablation, and 63% of those with only scar ablation. CONCLUSION:Patients with recurrent PMVT/VF and SHD often have a low-voltage scar associated with PVCs or inducible SMVT, which may also be the substrate for PMVT/VF. When present, substrate ablation targeting scar is a reasonable option for treatment of PMVT/VF even if PVCs are absent.
Authors: J Lukas Laws; Megan C Lancaster; M Ben Shoemaker; William G Stevenson; Rebecca R Hung; Quinn Wells; D Marshall Brinkley; Sean Hughes; Katherine Anderson; Dan Roden; Lynne W Stevenson Journal: Circ Res Date: 2022-05-26 Impact factor: 23.213
Authors: David E Krummen; Gordon Ho; Kurt S Hoffmayer; Franz N Schweis; Tina Baykaner; A J Rogers; Frederick T Han; Jonathan C Hsu; Mohan N Viswanathan; Paul J Wang; Wouter-Jan Rappel; Sanjiv M Narayan Journal: Circ Arrhythm Electrophysiol Date: 2021-02-07
Authors: M Martinek; M Manninger; R Schönbauer; D Scherr; C Schukro; H Pürerfellner; A Petzl; B Strohmer; M Derndorfer; E Bisping; M Stühlinger; L Fiedler Journal: Int J Cardiol Heart Vasc Date: 2021-04-03
Authors: Michel Haissaguerre; Ghassen Cheniti; Meleze Hocini; Frederic Sacher; F Daniel Ramirez; Hubert Cochet; Laura Bear; Romain Tixier; Josselin Duchateau; Rick Walton; Elodie Surget; Tsukasa Kamakura; Hugo Marchand; Nicolas Derval; Pierre Bordachar; Sylvain Ploux; Takamitsu Takagi; Thomas Pambrun; Pierre Jais; Louis Labrousse; Mark Strik; Hiroshi Ashikaga; Hugh Calkins; Ed Vigmond; Koonlawee Nademanee; Olivier Bernus; Remi Dubois Journal: Eur Heart J Date: 2022-03-21 Impact factor: 29.983
Authors: Vanessa Sciacca; Thomas Fink; Denise Guckel; Mustapha El Hamriti; Moneeb Khalaph; Martin Braun; Christian Sohns; Philipp Sommer; Guram Imnadze Journal: Front Cardiovasc Med Date: 2022-09-30
Authors: Matthew J Singleton; Prashant D Bhave; Elijah H Beaty; Natalie S Bradford; S Patrick Whalen Journal: J Innov Card Rhythm Manag Date: 2021-05-15